- Home
- KAVL vs PHIO Comparison
KAVL vs PHIO Comparison
Compare KAVL & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAVL
- PHIO
- Stock Information
- Founded
- KAVL 1998
- PHIO 2011
- Country
- KAVL United States
- PHIO United States
- Employees
- KAVL N/A
- PHIO N/A
- Industry
- KAVL Medicinal Chemicals and Botanical Products
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- KAVL Health Care
- PHIO Health Care
- Exchange
- KAVL Nasdaq
- PHIO Nasdaq
- Market Cap
- KAVL 7.9M
- PHIO 8.6M
- IPO Year
- KAVL N/A
- PHIO N/A
- Fundamental
- Price
- KAVL $0.49
- PHIO $2.16
- Analyst Decision
- KAVL
- PHIO Strong Buy
- Analyst Count
- KAVL 0
- PHIO 2
- Target Price
- KAVL N/A
- PHIO $9.00
- AVG Volume (30 Days)
- KAVL 26.0K
- PHIO 703.0K
- Earning Date
- KAVL 06-10-2025
- PHIO 08-13-2025
- Dividend Yield
- KAVL N/A
- PHIO N/A
- EPS Growth
- KAVL N/A
- PHIO N/A
- EPS
- KAVL N/A
- PHIO N/A
- Revenue
- KAVL $1,698,426.00
- PHIO N/A
- Revenue This Year
- KAVL N/A
- PHIO N/A
- Revenue Next Year
- KAVL N/A
- PHIO N/A
- P/E Ratio
- KAVL N/A
- PHIO N/A
- Revenue Growth
- KAVL N/A
- PHIO N/A
- 52 Week Low
- KAVL $0.46
- PHIO $0.97
- 52 Week High
- KAVL $1.95
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- KAVL 36.05
- PHIO 50.19
- Support Level
- KAVL $0.52
- PHIO $2.11
- Resistance Level
- KAVL $0.56
- PHIO $2.30
- Average True Range (ATR)
- KAVL 0.03
- PHIO 0.21
- MACD
- KAVL -0.00
- PHIO -0.04
- Stochastic Oscillator
- KAVL 0.57
- PHIO 9.65
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.